An ISN Bellagio Summit - Preventing vascular diseases around the world

December 07, 2005

During a unique, multidisciplinary and strategic 3-day Summit meeting the ISN - in collaboration with the International Diabetes Federation, the World Heart Federation, the International Society of Hypertension, the International Atherosclerosis Society, and representatives from WHO and the EU - will once again pioneer prevention.

Convening a group of 26 thought leaders and decision makers drawn equally from the developed and developing worlds, discussions will focus on how best to manage the growing burden of chronic renal disease and associated vascular diseases.

Supported by a grant from the prestigious Rockefeller Foundation, this ISN Summit meeting has been specifically crafted to tackle the alarming global shift in the leading causes of death. Nutritional deficiency and infectious diseases no longer account for the highest mortality statistics: the new leaders are non-communicable diseases, with cardiovascular disease rating as the deadliest of all.

The accelerating rates of chronic non-communicable diseases such as cardiovascular disease, diabetes, obesity, hypertension, and chronic renal disease are racing out of control, and for many nations, the burden is already too heavy to bear.

Structured to address this shift and rise to the challenge of managing the global burden of vascular diseases, the Summit's 3-day program reflects developed and developing world perspectives. The meeting will conclude with a workshop focused on establishing a consensus statement and the formulation of concrete recommendations for implementation.

Program Topics will include:

"WHO perspective", "Prevention of Cardiovascular disease, Diabetes and Chronic Kidney Disease" "Epidemic of diabetes" and several programs for prevention of vascular diseases in the emerging world will be highlighted referring to India, Venezuela, China, Pakistan and Africa.
-end-
For more information please contact:

Prof. Dr. Giuseppe Remuzzi, Mario Negri Institute for Pharmacological Research, Tel: +39 035 319888, gremuzzi@marionegri.it Amanda Wren, International Society of Nephrology, Tel: +32 473938672 amanda.wren@isn-online.org

Editors' Notes

1) In March 2004, ISN organized a first special strategic Summit to focus on the "Prevention of Renal Disease in the Emerging World: Toward Global Health Equality". This highly successful event was also generously hosted and supported by the Rockefeller Foundation in their retreat-style compound in Bellagio, Italy.

2) The International Society of Nephrology (ISN) is a not-for-profit society whose mission is the global advancement of nephrology. ISN promotes research and education to prevent and treat kidney disease throughout the world. Further information is available at www.isn-online.org or by calling +32-2-743 1546.

International Society of Nephrology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.